Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Corporate NewsBy adminJune 22, 2020
EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Regulatory DisclosuresBy adminJune 22, 2020
Rameda values the role played by the Egyptian Pharmacists Syndicate and Pharmacies in serving patients across Egypt Corporate NewsBy adminApril 28, 2020
Rameda issues statement regarding the “Stay Home to Protect your Family and Community” initiative Corporate NewsBy adminApril 28, 2020
Rameda launches initiative for the complementary dispensary and home delivery of medication at no cost, underlining its dedication to ensuring the healthcare and safety of some of Egypt’s most immune-compromised patient populations amid the COVID-19 pandemic Corporate NewsBy adminApril 26, 2020
EGX disclosure regarding the upcoming AGM on 10 May 2020 Regulatory DisclosuresBy adminApril 15, 2020
